Pain Management Drugs Market Key Players| Novartis AG, Abbott Laboratories, Endo Health Solutions, Inc., Purdue Pharma L.P., Pfizer, Inc.

A Comprehensive research study conducted by KD Market Insights on " Pain Management Drugs Market by Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Antimigraine Agents, Antidepressants, Opioids [Tramadol, Hydrocodone, Oxycodone, and Others], and Nonnarcotic Analgesics) and Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, and Fibromyalgia) - Global Opportunity Analysis and Industry Forecast, 2017-2023" report offers extensive and highly detailed historical, current and future market trends in the global and regional/market. The Pain Management Drugs Market report includes market size, growth drivers, barriers, opportunities, trends and other information which helps to find new opportunities in this market for the growth of the business through new technologies and developments.

Pain management is a branch of medicine, which employs approach to ease the suffering and improve the quality of life of individuals suffering from pain. Pain can be classified based on its occurrence and duration along with the affected body part. First line of treatment for pain management is pharmaceutical therapeutics or pain killer drugs, most of which are well-known brands. The global pain management drugs market was valued at $58,577 million in 2016, and is estimated to reach $77,131 million by 2023, registering a CAGR of 4% from 2017 to 2023.

Request for Sample @ https://www.kdmarketinsights.com/sample/4346 
 
Rise in geriatric population is the major factor that drives the growth of the global pain management market, as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, surge in prevalence of chronic diseases such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth.

Furthermore, increase in number of surgical procedures and rise in healthcare expenditure are expected to fuel the growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.

The global pain management drugs market is segmented based on drug class, indication, and geography. On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, antimigraine agents, antidepressants, opioids, and nonnarcotic analgesics. Opioids are further classified into tramadol, hydrocodone, oxycodone, and others (fentanyl, morphine, meperidine, codeine, and methadone). By indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, and fibromyalgia. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
- This report offers a detailed quantitative analysis of the current & future market trends from 2016 to 2023 to identify the prevailing opportunities.
- The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
- The global pain management drugs market is comprehensively analyzed with respect to drug class, indication, and geography.
- In-depth analysis based on geography facilitates to analyze the regional trends to assist in strategic business planning.
- The developmental strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.

KEY PLAYERS PROFILED
- Novartis AG
- Eli Lilly & Company
- Abbott Laboratories
- Endo Health Solutions, Inc.
- Purdue Pharma L.P.
- Pfizer, Inc.
- F. Hoffmann La Roche Ltd.
- Merck & Co. Inc.
- Johnson & Johnson
- GlaxoSmithKline Plc.

KEY MARKET SEGMENTS
By Drug Class
- NSAIDs
- Anesthetics
- Anticonvulsants
- Antimigraine Agents
- Antidepressants
- Opioids
- - - Tramadol
- - - Hydrocodone
- - - Oxycodone
- - - Others
- Nonnarcotic Analgesics

By Indication
- Arthritic Pain
- Neuropathic Pain
- Cancer Pain
- Chronic Back Pain
- Postoperative Pain
- Migraine
- Fibromyalgia

By Geography
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- Rest of Asia-Pacific
LAMEA
- Brazil
- Republic of South Africa
- Saudi Arabia
- Rest of LAMEA

The other players operating in the pain management drugs market include (companies not profiled in the report):
- Allergen Inc.
- Bayer AG
- Bristol-Myers Squibb
- Valeant Pharmaceuticals International Inc.
- Boehringer Ingelheim
- Sorrento Therapeutics
- WEX Pharmaceuticals
- Zynerba Pharmaceuticals

Browse Full Report with TOC @ https://www.kdmarketinsights.com/product/pain-management-therapeutics-market-amr
Table of Contents:

CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATION AND REIMBURSEMENT SCENARIO
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.1.1. Favorable regulatory scenario
3.5.1.2. Increase in geriatric population
3.5.1.3. Rise in incidence of chronic diseases
3.5.2. Restraints
3.5.2.1. Availability of alternative therapies
3.5.2.2. Drug exploitation
3.5.2.3. Patent expiration of prescription drugs
3.5.3. Opportunities
3.5.3.1. Advancements in drug development
3.5.3.2. Untapped markets in developing economies

CHAPTER 4 PAIN MANAGEMENT DRUGS MARKET, BY DRUG TYPE
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. NSAIDS
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.3. ANESTHETICS
4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.4. ANTICONVULSANTS
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
4.5. ANTI-MIGRAINE AGENTS
4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast
4.6. ANTIDEPRESSANTS
4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast
4.7. OPIOIDS
4.7.1. Key market trends
4.7.2. Key growth factors and opportunities
4.7.3. Market size and forecast
4.7.4. Tramadol
4.7.5. Hydrocodone
4.7.6. Oxycodaone
4.7.7. Others
4.8. NON-NARCOTIC ANALGESICS
4.8.1. Key market trends
4.8.2. Key growth factors and opportunities
4.8.3. Market size and forecast

CHAPTER 5 PAIN MANAGEMENT DRUGS MARKET, BY INDICATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. ARTHRITIC PAIN
5.2.1. Market size and forecast
5.3. NEUROPATHIC PAIN
5.3.1. Market size and forecast
5.4. CANCER PAIN
5.4.1. Market size and forecast
5.5. CHRONIC BACK PAIN
5.5.1. Market size and forecast
5.6. POST-OPERATIVE PAIN
5.6.1. Market size and forecast
5.7. MIGRAINE
5.7.1. Market size and forecast
5.8. FIBROMYALGIA
5.8.1. Market size and forecast

CHAPTER 6 PAIN MANAGEMENT DRUGS MARKET, BY GEOGRAPHY
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast by country
6.2.4. Market size and forecast by drug class
6.2.5. Market size and forecast by indications
6.2.5.1. U.S. market size and forecast by drug class
6.2.5.2. U.S. market size and forecast by indication
6.2.5.3. Canada market size and forecast by drug class
6.2.5.4. Canada market size and forecast by indication
6.2.5.5. Mexico market size and forecast by drug class
6.2.5.6. Mexico market size and forecast by indication
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast by country
6.3.4. Market size and forecast by drug class
6.3.5. Market size and forecast by indication
6.3.5.1. UK market size and forecast by drug class
6.3.5.2. UK market size and forecast by indication
6.3.5.3. France market size and forecast by drug class
6.3.5.4. France market size and forecast by indication
6.3.5.5. Germany market size and forecast by drug class
6.3.5.6. Germany market size and forecast by indication
6.3.5.7. Italy market size and forecast by drug class
6.3.5.8. Italy market size and forecast by indication
6.3.5.9. Spain market size and forecast by drug class
6.3.5.10. Spain market size and forecast by indication
6.3.5.11. Rest of Europe market size and forecast by drug class
6.3.5.12. Rest of Europe market size and forecast by indication
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast by country
6.4.4. Market size and forecast by drug class
6.4.5. Market size and forecast by indications
6.4.5.1. Japan market size and forecast by drug class
6.4.5.2. Japan market size and forecast by indication
6.4.5.3. China market size and forecast by drug class
6.4.5.4. China market size and forecast by indication
6.4.5.5. Australia market size and forecast by drug class
6.4.5.6. Australia market size and forecast by indication
6.4.5.7. South Korea market size and forecast by drug class
6.4.5.8. South Korea market size and forecast by indication
6.4.5.9. India market size and forecast by drug class
6.4.5.10. India market size and forecast by indication
6.4.5.11. Taiwan market size and forecast by drug class
6.4.5.12. Taiwan market size and forecast by indication
6.4.5.13. Rest of Asia-Pacific market size and forecast by drug class
6.4.5.14. Rest of Asia-Pacific market size and forecast by indication
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast by country
6.5.4. Market size and forecast by drug class
6.5.5. Market size and forecast by indication
6.5.5.1. Brazil market size and forecast by drug class
6.5.5.2. Brazil market size and forecast by indication
6.5.5.3. South Africa market size and forecast by drug class
6.5.5.4. South Africa market size and forecast by indication
6.5.5.5. Saudi Arabia market size and forecast by drug class
6.5.5.6. Saudi Arabia market size and forecast by indication
6.5.5.7. Rest of LAMEA market size and forecast by drug class
6.5.5.8. Rest of LAMEA market size and forecast by indication
Continue….
 
Check for Discount @ https://www.kdmarketinsights.com/discount/4346 

Contact Us:
 
KD Market Insights
90 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: info@kdmarketinsights.com 
Website: www.kdmarketinsights.com 
Read More News: https://consumersgoods745245330.wordpress.com/
https://ictindustry9.blogspot.com/ 

About Us:

KD Market Insights is one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on global industries, companies, products, and trends. Our in-house research experts have a wealth of knowledge in their respective domains. With KD Market Research, you always have the choice of getting customized report free of cost (up to 10%). Our support team will help you customize the report and scope as per your business needs. This ensures that you are making the right purchase decision.
Our clients list includes various Fortune 500 companies and leading advisory firms.

This release was published on openPR.